Shots: Takeda has signed an agreement with Celltrion to divest 18 select OTC and prescription pharmaceutical assets exclusively commercialized in the Asia Pacific under which Takeda will receive $266M as […]readmore
Tags : Assets
Shots: Aspen to receive $330.68M up front along with up to $110.22M deferred consideration upon fulfillment of certain conditions, making a total deal value ~$440.9M. The transaction is anticipated to […]readmore
Shots: Varian acquires the Boston Scientific drug-loadable microsphere (Oncozene/Embozene Tandem) and bland embolic (Embozene) bead products for the treatment of arteriovenous malformations and hypervascular tumors for $90M The focus of […]readmore
Shots: GSK to receive $10.6M as termination fees and up to $7.907M as regulatory milestone for its VLA15. Valneva to regain complete control of its R&D assets including its Lyme […]readmore